Project Details
Projekt
Therapy assessment in prostate cancer using imaging surrogate markers for the PI3K-AKT-mTORC- and AR-pathway (B11*)
Subject Area
Nuclear Medicine, Radiotherapy, Radiobiology
Term
from 2017 to 2021
Project identifier
Deutsche Forschungsgemeinschaft (DFG) - Project number 68647618
Recurrent prostate cancer commonly being treated with different androgen-receptor(AR)-modulating agents is highly expressing the prostate-specific-membrane-antigen (PSMA) constituting an ideal target for imaging and radioligand therapy. The primary aim of this project is to investigate PSMA-ligand PET as potential surrogate marker for activity of the PI3K-AKT-mTORC and AR-receptor axis and to develop and evaluate probes for differentiation of androgen-dependent (AD) and CRPC (κ-opioid receptor agonists, Prostatic Acid Phosphatase). Potential pre-targeting of PSMA under AR-targeted therapy as well as additive effect of radiosensitizer on PSMA radioligand therapy will be assessed.
DFG Programme
Collaborative Research Centres
Applicant Institution
Technische Universität München
Project Heads
Professor Dr. Matthias Eiber; Professor Dr. Hans-Jürgen Wester
